Demyelinating Diseases
18
3
3
8
Key Insights
Highlights
Success Rate
89% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
5.6%
1 terminated out of 18 trials
88.9%
+2.4% vs benchmark
6%
1 trials in Phase 3/4
13%
1 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 8 completed trials
Clinical Trials (18)
Assessing Changes in Multi-parametric MRI in Patients With Acute Demyelinating Lesions Taking Clemastine Fumarate as a Myelin Repair Therapy
Institutional Registry of Rare Diseases
Contrast-enhanced 3D T1-weighted Gradient-echo Versus Spin-echo 3 Tesla MR Sequences in the Detection of Active Multiple Sclerosis Lesions
Aerobic Exercise for Remyelination in Multiple Sclerosis
Cell-Based Therapy for White Matter Repair in Periventricular Leukomalacia
IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis
Ukulele Playing to Improve Cognition in People with Multiple Sclerosis: a Feasibility Study
Upper Extremity Function in Multiple Sclerosis Patients With Advanced Disability Treated With Ocrevus
Comparison of Diagnostic Performances of 3D FLAIR, DIR and PSIR Sequences in Optic Neuritis
Power Training in Older Multiple Sclerosis Patients
Non-inferiority Study of Rituximab Compared to Ocrelizumab in Relapsing MS
Acute Optic Neuritis Network: an International Study That Invesitages Subjects With a First-ever Episode of Acute Inflammation of the Optic Nerve
Pediatric Patient Experience on a Diagnostic Path
Humoral and T-Cell Responses to COVID-19 Vaccination in Multiple Sclerosis Patients Treated With Ocrelizumab Treated With Ocrelizumab or Natalizumab
Natural History Study of Children With Metachromatic Leukodystrophy
Oligodendrocyte Progenitor Cell Culture From Human Brain
Autologous Mesenchymal Stem Cells From Adipose Tissue in Patients With Secondary Progressive Multiple Sclerosis
Intravenous Immunoglobulin (IVIg) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)